Moreover, SOX2 overexpression occurs not only in high-grade serous ovarian tumors, but also in pre-malignant, fallopian tube epithelial cells from BRCA1/BRCA2 mutation carriers who underwent prophylactic salpingo-oophorectomy [71] – opening the possibility for considering LSD1-targeted epigenetic approaches such as iadademstat for breast/ovarian cancer prevention. Here, BRCA2 is linked to ovarian carcinoma.